Gofen & Glossberg LLC IL Has $2.25 Million Holdings in Teva Pharmaceutical Industries Limited (TEVA)

Gofen & Glossberg LLC IL cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 22.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 67,651 shares of the company’s stock after selling 20,117 shares during the period. Gofen & Glossberg LLC IL’s holdings in Teva Pharmaceutical Industries Limited were worth $2,247,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of TEVA. American International Group Inc. acquired a new stake in Teva Pharmaceutical Industries Limited in the first quarter valued at $523,000. Cornerstone Capital Management Holdings LLC. acquired a new stake in Teva Pharmaceutical Industries Limited in the first quarter valued at $596,000. Teachers Advisors LLC raised its stake in Teva Pharmaceutical Industries Limited by 6.1% in the first quarter. Teachers Advisors LLC now owns 642,314 shares of the company’s stock valued at $20,612,000 after buying an additional 36,900 shares in the last quarter. Legal & General Group Plc raised its stake in Teva Pharmaceutical Industries Limited by 5.8% in the first quarter. Legal & General Group Plc now owns 590,102 shares of the company’s stock valued at $18,936,000 after buying an additional 32,515 shares in the last quarter. Finally, Thrivent Financial For Lutherans raised its stake in Teva Pharmaceutical Industries Limited by 28.2% in the first quarter. Thrivent Financial For Lutherans now owns 142,420 shares of the company’s stock valued at $4,571,000 after buying an additional 31,300 shares in the last quarter. Institutional investors own 56.75% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/15/gofen-glossberg-llc-il-has-2-25-million-holdings-in-teva-pharmaceutical-industries-limited-teva.html.

A number of research firms have weighed in on TEVA. Royal Bank Of Canada cut their price target on Teva Pharmaceutical Industries Limited from $21.00 to $15.00 and set an “underperform” rating on the stock in a research note on Monday, September 18th. Wells Fargo & Company reiterated a “market perform” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, October 5th. Credit Suisse Group set a $39.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Maxim Group reiterated a “hold” rating and set a $15.50 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, September 14th. Finally, Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a research report on Thursday, June 22nd. Five research analysts have rated the stock with a sell rating, eighteen have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $27.63.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down 1.12% on Friday, reaching $14.98. The company’s stock had a trading volume of 27,439,869 shares. The stock’s market capitalization is $15.22 billion. Teva Pharmaceutical Industries Limited has a 1-year low of $14.30 and a 1-year high of $44.42. The stock has a 50-day moving average of $16.73 and a 200 day moving average of $26.10.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm’s revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.25 EPS. On average, equities analysts forecast that Teva Pharmaceutical Industries Limited will post $4.24 EPS for the current year.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply